Moreover, some anti-IL-17A monoclonal antibodies could improve RA signs and symptoms in RA patients, and no strong adverse safety signals were noted (Genovese et al., 2010; Genovese et al., 2014). This evidence concerns the gene IL17A and rheumatoid arthritis.